Literature DB >> 1893618

Impaired tumour necrosis factor-alpha (TNF-alpha) production and abnormal B cell response to TNF-alpha in patients with systemic lupus erythematosus (SLE).

K Mitamura1, H Kang, Y Tomita, H Hashimoto, S Sawada, T Horie.   

Abstract

We examined the TNF-alpha activity in culture supernatants of monocytes isolated from the peripheral blood of patients with SLE and of normal individuals. The monocytes from patients with SLE stimulated with silica particles, lipopolysaccharide or Staphylococcus aureus Cowan 1 secreted significantly lower amounts of TNF-alpha than did normal monocytes. A decreased TNF mRNA expression was observed in peripheral blood mononuclear cells stimulated by mitogens from patients with SLE. Furthermore, we examined the effect of recombinant TNF-alpha (rTNF-alpha) on the B cell function in SLE patients. rTNF-alpha inhibited the spontaneous B cell proliferation of SLE, but tended to enhance the normal B cell proliferation. Spontaneous IgM production from SLE B cells was inhibited by rTNF-alpha, but that from normal B cells was not. Spontaneous IgG production was unaffected by rTNF-alpha. Also, rTNF-alpha did not affect the viability of B cells. These findings suggest that an impaired TNF-alpha production and an abnormal B cell response to TNF-alpha play a role in the immunological dysfunction in patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1893618      PMCID: PMC1535612          DOI: 10.1111/j.1365-2249.1991.tb05736.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Effects of interferon-gamma and tumor necrosis factor-alpha on the expression of an Ia antigen on a murine macrophage cell line.

Authors:  R J Chang; S H Lee
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

2.  The lupus activity criteria count (LACC).

Authors:  M B Urowitz; D D Gladman; E C Tozman; C H Goldsmith
Journal:  J Rheumatol       Date:  1984-12       Impact factor: 4.666

3.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.

Authors:  D Pennica; G E Nedwin; J S Hayflick; P H Seeburg; R Derynck; M A Palladino; W J Kohr; B B Aggarwal; D V Goeddel
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

4.  Impaired T-cell activation in patients with systemic lupus erythematosus.

Authors:  S Sierakowski; E J Kucharz; R W Lightfoot; J S Goodwin
Journal:  J Clin Immunol       Date:  1989-11       Impact factor: 8.317

5.  Tumor necrosis factors alpha and beta differ in their capacities to generate interleukin 1 release from human endothelial cells.

Authors:  R M Locksley; F P Heinzel; H M Shepard; J Agosti; T E Eessalu; B B Aggarwal; J M Harlan
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

6.  Aberration of monokine production and monocyte subset in patients with systemic lupus erythematosus.

Authors:  M Takei; H Kang; K Tomura; S Amaki; M Hirata; M Karasaki; S Sawada; I Amaki
Journal:  J Clin Lab Immunol       Date:  1987-04

7.  Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis.

Authors:  C O Jacob; H O McDevitt
Journal:  Nature       Date:  1988-01-28       Impact factor: 49.962

8.  B cell hyperactivity and its relation to distinct clinical features and the degree of disease activity in patients with systemic lupus erythematosus.

Authors:  T Sakane; N Suzuki; S Takada; Y Ueda; Y Murakawa; T Tsuchida; Y Yamauchi; T Kishimoto
Journal:  Arthritis Rheum       Date:  1988-01

9.  Effect of interferon-gamma and tumor necrosis factor on the expression of class I and class II major histocompatibility molecules by cultured human umbilical vein endothelial cells.

Authors:  J F Wedgwood; L Hatam; V R Bonagura
Journal:  Cell Immunol       Date:  1988-01       Impact factor: 4.868

10.  Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells.

Authors:  K Pfizenmaier; P Scheurich; C Schlüter; M Krönke
Journal:  J Immunol       Date:  1987-02-01       Impact factor: 5.422

View more
  6 in total

Review 1.  Cytokines and systemic lupus erythematosus.

Authors:  G S Dean; J Tyrrell-Price; E Crawley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

2.  Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.

Authors:  Paola Caramaschi; Domenico Biasi; Elisabetta Tonolli; Sara Pieropan; Nicola Martinelli; Antonio Carletto; Alessandro Volpe; Lisa Maria Bambara
Journal:  Rheumatol Int       Date:  2005-02-23       Impact factor: 2.631

3.  Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.

Authors:  Paola Caramaschi; Domenico Biasi; Marco Colombatti; Sara Pieropan; Nicola Martinelli; Antonio Carletto; Alessandro Volpe; Luisa Maria Pacor; Lisa Maria Bambara
Journal:  Rheumatol Int       Date:  2004-12-31       Impact factor: 2.631

4.  The monocyte tumor necrosis factor-alpha production in patients with acute leukemia in complete remission.

Authors:  M Aiso; Y Iizuka; H I Kang; S Sawada; T Ohshima; T Horie
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

5.  Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study.

Authors:  Naoichiro Yukawa; Takao Fujii; Seiko Kondo-Ishikawa; Hajime Yoshifuji; Daisuke Kawabata; Takaki Nojima; Koichiro Ohmura; Takashi Usui; Tsuneyo Mimori
Journal:  Arthritis Res Ther       Date:  2011-12-22       Impact factor: 5.156

6.  Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation.

Authors:  E Waszczykowska; E Robak; A Wozniacka; J Narbutt; J D Torzecka; A Sysa-Jedrzejowska
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.